HOPA 2019: Flat-Dose Nivolumab + Weight-Based Low-Dose Ipilimumab Is a Safe and Effective Alternative to Weight-Based Dosing as First-Line Treatment of NSCLC
The regimen may be more convenient for patients and providers.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.